Who
Casdin Capital, LLC
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, GeneDx Holdings; 10% owner, BioLife Solutions; Director and 10% owner, Standard BioTools; Director, 2seventy bio; Director, Tenaya Therapeutics; 10% owner, MaxCyte; Director, Absci.
In numbers
- Trades disclosed
- 32
- Buys
- 13
- Sells
- 3
- Bought
- $109.3M
- Sold
- $30.6M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 24 Nov 2020
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $2.6M50,000 at $52.86 | filing |
| 4 Jun 2026filed 8 Jun 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $8.5M150,000 at $56.44 | filing |
| 20 May 2026filed 20 May 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $6.1M140,000 at $43.81 | filing |
| 19 May 2026filed 20 May 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $7.9M185,000 at $42.60 | filing |
| 18 May 2026filed 20 May 2026 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $7.4M175,000 at $42.55 | filing |
| 11 May 2026filed 11 May 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code P | —50,000 | filing |
| 8 May 2026filed 11 May 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code P | —300,000 | filing |
| 7 May 2026filed 11 May 2026 | WGS GeneDx Holdingsoption or derivative · Providers & Facilities | SEC FORM 4 Code P | —500,000 | filing |
| 15 Aug 2025filed 21 Aug 2025 | BioLife SolutionsMedical Devices | SEC FORM 4 Sold | $12.2M500,000 at $24.40 | filing |
| 28 Feb 2025filed 4 Mar 2025 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Bought | $5.2M4,820,959 at $1.07 | filing |
| 28 Feb 2025filed 4 Mar 2025 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code J | $583K545,000 at $1.07 | filing |
| 28 Feb 2025filed 4 Mar 2025 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code J | $583K545,000 at $1.07 | filing |
| 28 Feb 2025filed 4 Mar 2025 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code A | $62K58,215 at $1.07 | filing |
| 18 Jun 2024filed 21 Jun 2024 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code J | $1.3M655,000 at $2.05 | filing |
| 18 Jun 2024filed 21 Jun 2024 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code J | $1.1M545,000 at $2.05 | filing |
| 18 Jun 2024filed 21 Jun 2024 | LAB Standard BioToolsLife-science tools | SEC FORM 4 Code J | $2.5M1,200,000 at $2.05 | filing |
| 4 Jun 2024filed 5 Jun 2024 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $676K30,000 at $22.52 | filing |
| 3 Jun 2024filed 5 Jun 2024 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $2.1M100,000 at $20.82 | filing |
| 13 May 2024filed 15 May 2024 | WGS GeneDx HoldingsProviders & Facilities | SEC FORM 4 Bought | $1.2M50,000 at $23.31 | filing |
| 26 Mar 2024filed 28 Mar 2024 | 2seventy bio | SEC FORM 4 Bought | $204K40,000 at $5.10 | filing |
News
No headline names them, or the companies they trade most, lately.